290 related articles for article (PubMed ID: 25762476)
1. The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes.
Vissers PA; Cardwell CR; van de Poll-Franse LV; Young IS; Pouwer F; Murray LJ
Breast Cancer Res Treat; 2015 Apr; 150(2):427-37. PubMed ID: 25762476
[TBL] [Abstract][Full Text] [Related]
2. Metformin use and survival after colorectal cancer: A population-based cohort study.
Mc Menamin ÚC; Murray LJ; Hughes CM; Cardwell CR
Int J Cancer; 2016 Jan; 138(2):369-79. PubMed ID: 26331456
[TBL] [Abstract][Full Text] [Related]
3. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
Bo S; Castiglione A; Ghigo E; Gentile L; Durazzo M; Cavallo-Perin P; Ciccone G
Eur J Endocrinol; 2013 Jul; 169(1):117-26. PubMed ID: 23660643
[TBL] [Abstract][Full Text] [Related]
4. Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study.
Morgan CL; Mukherjee J; Jenkins-Jones S; Holden SE; Currie CJ
Diabetes Obes Metab; 2014 Oct; 16(10):957-62. PubMed ID: 24720708
[TBL] [Abstract][Full Text] [Related]
5. Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients.
Bo S; Ciccone G; Rosato R; Villois P; Appendino G; Ghigo E; Grassi G
Diabetes Obes Metab; 2012 Jan; 14(1):23-9. PubMed ID: 21812892
[TBL] [Abstract][Full Text] [Related]
6. Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus.
Qiu H; Rhoads GG; Berlin JA; Marcella SW; Demissie K
Diabetes Obes Metab; 2013 Apr; 15(4):349-57. PubMed ID: 23137378
[TBL] [Abstract][Full Text] [Related]
7. Type of preadmission antidiabetic treatment and outcome among patients with ischemic stroke: a nationwide follow-up study.
Horsdal HT; Mehnert F; Rungby J; Johnsen SP
J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):717-25. PubMed ID: 21536457
[TBL] [Abstract][Full Text] [Related]
8. Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study.
Calip GS; Yu O; Elmore JG; Boudreau DM
Cancer Causes Control; 2016 May; 27(5):709-20. PubMed ID: 27053250
[TBL] [Abstract][Full Text] [Related]
9. Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma.
Rieken M; Xylinas E; Kluth L; Crivelli JJ; Chrystal J; Faison T; Lotan Y; Karakiewicz PI; Sun M; Fajkovic H; Babjuk M; Bachmann A; Scherr DS; Shariat SF
Urol Oncol; 2014 Jan; 32(1):49.e7-14. PubMed ID: 24140245
[TBL] [Abstract][Full Text] [Related]
10. The effect of metformin on mortality following cancer among patients with diabetes.
Lega IC; Shah PS; Margel D; Beyene J; Rochon PA; Lipscombe LL
Cancer Epidemiol Biomarkers Prev; 2014 Oct; 23(10):1974-84. PubMed ID: 25030683
[TBL] [Abstract][Full Text] [Related]
11. Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: a population-based cohort study among British women.
Redaniel MT; Jeffreys M; May MT; Ben-Shlomo Y; Martin RM
Cancer Causes Control; 2012 Nov; 23(11):1785-95. PubMed ID: 22971998
[TBL] [Abstract][Full Text] [Related]
12. Type 2 diabetes, breast cancer specific and overall mortality: Associations by metformin use and modification by race, body mass, and estrogen receptor status.
Lee KN; Torres MA; Troeschel AN; He J; Gogineni K; McCullough LE
PLoS One; 2020; 15(5):e0232581. PubMed ID: 32369516
[TBL] [Abstract][Full Text] [Related]
13. Metformin use and survival from lung cancer: A population-based cohort study.
Menamin ÚC; Cardwell CR; Hughes CM; Murray LM
Lung Cancer; 2016 Apr; 94():35-9. PubMed ID: 26973204
[TBL] [Abstract][Full Text] [Related]
14. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study.
Gulliford M; Latinovic R
Diabetes Metab Res Rev; 2004; 20(3):239-45. PubMed ID: 15133756
[TBL] [Abstract][Full Text] [Related]
15. Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer.
Rieken M; Xylinas E; Kluth L; Crivelli JJ; Chrystal J; Faison T; Lotan Y; Karakiewicz PI; Fajkovic H; Babjuk M; Kautzky-Willer A; Bachmann A; Scherr DS; Shariat SF
BJU Int; 2013 Dec; 112(8):1105-12. PubMed ID: 24053906
[TBL] [Abstract][Full Text] [Related]
16. Metformin and cancer-specific survival among breast, colorectal, or endometrial cancer patients: A nationwide data linkage study.
Feng JL; Qin X
Diabetes Res Clin Pract; 2021 May; 175():108755. PubMed ID: 33836207
[TBL] [Abstract][Full Text] [Related]
17. Associations between diabetes medication use and risk of second breast cancer events and mortality.
Calip GS; Yu O; Hoskins KF; Boudreau DM
Cancer Causes Control; 2015 Aug; 26(8):1065-77. PubMed ID: 25956271
[TBL] [Abstract][Full Text] [Related]
18. No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK.
Kowall B; Stang A; Rathmann W; Kostev K
Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):865-74. PubMed ID: 26132313
[TBL] [Abstract][Full Text] [Related]
19. Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial.
Tsilidis KK; Capothanassi D; Allen NE; Rizos EC; Lopez DS; van Veldhoven K; Sacerdote C; Ashby D; Vineis P; Tzoulaki I; Ioannidis JP
Diabetes Care; 2014 Sep; 37(9):2522-32. PubMed ID: 24898303
[TBL] [Abstract][Full Text] [Related]
20. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.
Mellbin LG; Malmberg K; Norhammar A; Wedel H; Rydén L;
Eur Heart J; 2008 Jan; 29(2):166-76. PubMed ID: 18156614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
